A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Phase 1 Active not recruiting 10 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).

Timeline

Start: 2025-05-07
Primary completion: 2027-05-26
Completion: 2027-05-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986489	Unknown	—	—

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications